Large-scale Mendelian randomization identifies novel pathways as therapeutic targets for heart failure with reduced ejection fraction and with preserved ejection fraction

Danielle Rasooly(Brigham and Women's Hospital), Juan P. Casas(Novartis (Switzerland)), Maik Pietzner(University of Freiburg), Patricia B. Munroe(Queen Mary University of London), Nicole Kosik(VA Boston Healthcare System), John C. Whittaker(University of Cambridge), Eric Farber‐Eger(Vanderbilt University), Claudia Giambartolomei(University College London), Alexandre C. Pereira(University of Washington), Andrew R. Leach(LifeArc), Gina M. Peloso(Boston University), Yan V. Sun(Utah State University), Brian R. Ferolito(VA Boston Healthcare System), Kelly Cho(VA Boston Healthcare System), Jacob Joseph(Lourdes Hospital), Gian Gaetano Tartaglia(Institució Catalana de Recerca i Estudis Avançats), Gabriele Proietti(Italian Institute of Technology), Claudia Langenberg(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Quinn S. Wells(Vanderbilt University), Nay Aung(Queen Mary University of London), Daniel J Golden(Brigham and Women's Hospital), Lawrence S. Phillips(Emory University), Steffen E. Petersen(Queen Mary University of London), Andréa R. V. R. Horimoto(Laboratory of Molecular Genetics), Giorgio Bini(Italian Institute of Technology), Peter W.F. Wilson(VA Tennessee Valley Healthcare System), John Michael Gaziano(Brigham and Women's Hospital), Hesam Dashti(Broad Institute)
medRxiv
March 24, 2024
Cited by 0


Related Papers